<ddi:DDIInstance xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="ddi:instance:3_3 http://ddialliance.org/Specification/DDI-Lifecycle/3.3/XMLSchema/instance.xsd" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ddi="ddi:instance:3_3" xmlns:r="ddi:reusable:3_3" xmlns:s="ddi:studyunit:3_3" xmlns:d="ddi:datacollection:3_3" xmlns:a="ddi:archive:3_3" xmlns:c="ddi:conceptualcomponent:3_3" xmlns:cm="ddi:comparative:3_3" xmlns:g="ddi:group:3_3" xmlns:l="ddi:logicalproduct:3_3" xmlns:p="ddi:physicaldataproduct:3_3" xmlns:pi="ddi:physicalinstance:3_3" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace" isMaintainable="true" scopeOfUniqueness="Agency">
  <r:URN>urn:ddi:se.researchdata:2024-444:1</r:URN>
  <r:Agency>SND</r:Agency>
  <r:ID>2024-444</r:ID>
  <r:Version>1</r:Version>
  <g:ResourcePackage>
    <r:URN>urn:ddi:se.researchdata:2024-444.ResourcePackage:2.0</r:URN>
    <r:OtherMaterialScheme>
      <r:URN>urn:ddi:se.researchdata:2024-444.OtherMaterialScheme:2.0</r:URN>
    </r:OtherMaterialScheme>
    <a:OrganizationScheme>
      <r:URN>urn:ddi:se.researchdata:2024-444.OrganizationScheme-0:2.0</r:URN>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2024-444.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Women's and Children's Health, Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Abishek</a:FirstGiven>
            <a:LastFamily>Arora</a:LastFamily>
            <a:FullName>
              <r:String>Abishek Arora</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0002-6149-4417</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2024-444.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Women's and Children's Health, Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Francesca</a:FirstGiven>
            <a:LastFamily>Mastropasqua</a:LastFamily>
            <a:FullName>
              <r:String>Francesca Mastropasqua</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0003-4237-2446</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2024-444.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Women's and Children's Health, Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Sven</a:FirstGiven>
            <a:LastFamily>Bölte</a:LastFamily>
            <a:FullName>
              <r:String>Sven Bölte</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0002-4579-4970</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2024-444.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Women's and Children's Health, Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Kristiina</a:FirstGiven>
            <a:LastFamily>Tammimies</a:LastFamily>
            <a:FullName>
              <r:String>Kristiina Tammimies</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0002-8324-4697</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
    </a:OrganizationScheme>
  </g:ResourcePackage>
  <s:StudyUnit>
    <r:URN>urn:ddi:se.researchdata:2024-444.StudyUnit:2.0</r:URN>
    <r:UserID typeOfUserID="datasetIdentifier">2024-444</r:UserID>
    <r:Citation>
      <r:Title>
        <r:String xml:lang="sv">Urine metabolomic profiles of autism and autistic traits – a twin study</r:String>
        <r:String xml:lang="en">Urine metabolomic profiles of autism and autistic traits – a twin study</r:String>
      </r:Title>
      <r:Creator>
        <r:CreatorReference>
          <r:URN>urn:ddi:se.researchdata:2024-444.Individual-0:2.0</r:URN>
          <r:TypeOfObject>Individual</r:TypeOfObject>
        </r:CreatorReference>
      </r:Creator>
      <r:Publisher>
        <r:PublisherName>
          <r:String xml:lang="sv">Karolinska Institutet</r:String>
          <r:String xml:lang="en">Karolinska Institutet</r:String>
        </r:PublisherName>
      </r:Publisher>
      <r:Publisher>
        <r:PublisherName>
          <r:String xml:lang="sv">Karolinska Institutet</r:String>
          <r:String xml:lang="en">Karolinska Institutet</r:String>
        </r:PublisherName>
      </r:Publisher>
      <r:PublicationDate>
        <r:SimpleDate>2024-08-02</r:SimpleDate>
      </r:PublicationDate>
      <r:InternationalIdentifier>
        <r:IdentifierContent>10.48723/6821-pn89</r:IdentifierContent>
        <r:ManagingAgency controlledVocabularyAgencyName="DOI">DOI</r:ManagingAgency>
      </r:InternationalIdentifier>
    </r:Citation>
    <r:Abstract>
      <r:Content xml:lang="sv">Datasetet består av två excel filer. En av dem (Full_Data_Arora...) innehåller data för 105 individer från studien beskriven nedan.  Den andra filen (Data_Arora...) är en delmängd av datasetet som innehåller data för de 48  kompletta tvillingpar från studien. 

I denna studie valdes individer (N=105) och 48 kompletta tvillingpar från RATSS-kohorten, som är ett tvillingurval berikat med neuropsykiatriska funktionsnedsättningar (NPF) rekryterade från den allmänna svenska befolkningen mellan juni 2011 och december 2015, för icke-riktad masspektrometribaserad metabolomik av urinprover. Detaljerade inklusions- och exklusionskriterier för RATSS har tidigare publicerats. Bland de rekryterade tvillingarna valde vi deltagare för denna studie baserat på autismdiagnosstatus, om tvillingparet var konkordant (båda med autismdiagnos) eller diskordant (endast en med autismdiagnos) och om de hade tillgängliga urinprover. Dessutom matchade vi de icke-autistiska tvillingparen efter ålder och kön. Studien godkändes av den svenska Etikprövningsmyndigheten (2016/1452-31). Skriftligt informerat samtycke erhölls från alla deltagare eller deras vårdnadshavare, beroende på deras ålder.
Under ett 2,5-dagars studiebesök genomförde ett team av kliniska experter en diagnostisk utvärdering av deltagarna i enlighet med riktlinjerna i Diagnostic and Statistical Manual of Mental Disorders, 5 (DSM-5). Utvärderingen använde en kombination av diagnostiska intervjuer, granskning av medicinska historiedokument och användning av etablerade diagnostiska verktyg. Detta inkluderade beteendebedömningsverktyg som Autism Diagnostic Interview-Revised (ADI-R) och Autism Diagnostic Observation Schedule 2nd Edition (ADOS-2). Dessutom användes ytterligare verktyg för att fastställa diagnoser av andra NPF, såsom Diagnostic Interview for ADHD in Adults (DIVA-2), Structured Clinical Interview for DSM-IV (SCID-IV) och Adaptive Behavior Assessment System (ABAS) – mer detaljerad information finns i publikationen av Bölte och kollegor (PMID: 24735654). Autistiska drag utvärderades med föräldrarapporterade versionen av Social Responsiveness Scale 2nd Edition (SRS-2), bestående av 65 punkter. Intelligenskvot (IQ) mättes med Wechsler Intelligence Scale for Children eller Adults - IV General Ability Index (GAI). Dessutom tillfrågades deltagarna om en lista över deras aktuella, regelbundet använda mediciner under studiebesöket. Eftersom det fanns en samling av olika mediciner inklusive antidepressiva och ADHD-mediciner, grupperades alla tillsammans och justerades för i våra analyser. Ingen undergruppering var möjlig för läkemedlen på grund av brist på kraft att upptäcka metabolomiska effekter av specifika läkemedel.
Urin uppsamling och metabolomik: Urinproverna samlades in den sista dagen av besöket från studiedeltagarna. Först informerades deltagarna om urinprovsamlingen i en särskild urinbägare. Urinbägaren gavs sedan till en forskningssjuksköterska som överförde 10 ml av den insamlade urinen till ett sterilt vakuumrör utan tillsatser. Provet transporterades sedan direkt, delades upp och lagrades i Karolinska Institutets biobank vid -80 °C. De insamlade proverna transporterades vidare för analys till Proteomics and Metabolomics Facility, University of Tuscia, Italien. Alla prover hanterades enligt samma angivna protokoll. Före metabolomanalysen mättes urinens specifika gravitation efter centrifugering vid 13 000 g i 10 minuter. Urinalikvoter (200 μl) blandades med 200 μl metanol:acetonitril (50:30:20), vortexades i 30 minuter, vid maximal hastighet vid 4 °C och centrifugerades sedan vid 16 000 g i 15 minuter vid 4 °C. Supernatanten samlades in för metabolomanalys. 
Ultra-High Performance Liquid Chromatography (UHPLC) För experimenten injicerades 20 µL av proverna i ett UPLC-system (Ultimate 3000, Thermo Scientific) och analyserades i positivt läge: prover laddades på en Reprosil C18-kolonn (2,0 mm × 150 mm, 2,5 μm - Dr Maisch, Tyskland) för separation av metaboliter. Kromatografiska separationer uppnåddes vid en kolonntemperatur av 30 °C och ett flödeshastighet på 0,2 mL/min. En linjär gradient (0–100%) av lösningsmedel A (ddH2O, 0,1% myrsyra) till B (acetonitril, 0,1% myrsyra) användes över 20 minuter, återgår till 100% lösningsmedel A på 2 minuter och en 6-minuters eftertid med lösningsmedel A. Acetonitril, myrsyra och HPLC-klass vatten köptes från Sigma Aldrich.
Högupplösande masspektrometri (HRMS) UPLC-systemet kopplades online med en masspektrometer, Q Exactive (Thermo Scientific), som skannade i full MS-läge (2 μ-skanningar) med en upplösning av 70 000 i intervallet 67 till 1000 m/z, mål på 1 × 106 joner och en maximal joninjektionstid (IT) på 35 ms, 3,8 kV sprutspänning, 40 skyddsgas och 25 hjälpgas, som användes i negativt och sedan positivt jonläge. Källjoniseringsparametrar var: sprutspänning, 3,8 kV; kapillär temperatur, 300 °C; och S-Lens nivå, 45. Kalibrering utfördes före varje analys mot positiva eller negativa jonlägeskalibreringsmixar (Piercenet, Thermo Fisher, Rockford, IL) för att säkerställa sub-ppm-fel av den intakta massan.
Metabolitmätning: Data normaliserades efter urinens specifika gravitation eftersom kreatininutsöndring kan vara onormalt reducerad hos autistiska barn [31]. Replikat exporterades som mzXML-filer och bearbetades genom MAVEN [32]. Masspektrometrikromatogram utarbetades för toppjustering, matchning och jämförelse av föräldra- och fragmentjoner, och tentativ metabolitidentifiering (inom ett 10-ppm massavvikelseintervall mellan observerade och förväntade resultat mot den importerade Kyoto Encyclopedia of Genes and Genomes (KEGG) databasen).</r:Content>
      <r:Content xml:lang="en">The dataset consists of two excel files.  One  (Full_Data_Arora...) contains data for all 105 individuals in the study described below.  The other (Data_Arora...) is a subset of the data containing the data for the  48 complete twins that were part of the study.

In this study, individuals (N=105) and 48 complete twin pairs were selected from the RATSS cohort , which is a neurodevelopmental condition (NDC) enriched twin sample recruited from the general Swedish population between June 2011 and December 2015, for untargeted mass spectrometry-based urine metabolomics. Detailed inclusion and exclusion criteria for RATSS have been previously published. Among the recruited twins, we selected participants for this study based on the autism diagnosis status, whether the twin pair was concordant (both with autism diagnosis) or discordant (only one with autism diagnosis) and if they had available urine samples. Furthermore, we age- and sex-matched the non-autistic twin pairs. The study was approved by the Swedish Ethical Review Authority (2016/1452-31). Written informed consent was obtained from all participants or their caregivers, based on their age.
During a 2.5-day study visit, a team of clinical professionals conducted a diagnostic evaluation of the participants in line with the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) guidelines. The evaluation utilised a combination of diagnostic interviews, a review of medical history documents, and the use of established diagnostic measures [19]. This included behavioural assessment tools such as the Autism Diagnostic Interview-Revised (ADI-R), the Autism Diagnostic Observation Schedule 2nd Edition (ADOS-2). Furthermore, additional tools were used to establish the diagnosis of other NDCs, if any, such the Diagnostic Interview for ADHD in Adults (DIVA-2), the Structured Clinical Interview for DSM-IV (SCID-IV), and the Adaptive Behavior Assessment System (ABAS)  – more detailed information about the same is available in the publication by Bölte and colleagues (PMID: 24735654). Autistic traits were evaluated with the parent-report version of the Social Responsiveness Scale 2nd Edition (SRS-2), consisting of 65 items. Intelligence quotient (IQ) was measured by using the Wechsler Intelligence Scale for Children or Adults - IV General Ability Index (GAI). Additionally, the participants were asked for a list of their current, regularly used medications during the study visit. As there was a collection of different medications including antidepressants and ADHD medication, all were grouped together and adjusted for in our analyses. No subgrouping was possible for the drugs due to lack of power to detect metabolomic effects of specific drugs.

Urine collection and metabolite extraction
The urine samples were collected at the last day of the visit from the study participants. First, the participants were informed about the urine sample collection into a special urine cup. The urine cup was then given to a research nurse who transferred 10 mL of the collected urine to a sterile vacutainer tube with no additives. The sample was then directly transported, aliquoted and stored in the Karolinska Institutet Biobank at -80 °C. The collected samples were further transported for analysis to the Proteomics and Metabolomics Facility, University of Tuscia, Italy. All samples were handled as per the same stated protocol. Before the metabolomic analysis, the urinary specific gravity was measured following centrifugation at 13,000 g for 10 minutes. Urine aliquots (200 μl) were mixed with 200 μl of methanol:acetonitrile:water (50:30:20), vortexed for 30 minutes, maximum speed at 4 °C and then centrifuged at 16,000 g for 15 minutes at 4 °C. Supernatants were collected for metabolomic analysis.

Ultra-High Performance Liquid Chromatography (UHPLC)
For the experiments, 20 µL of samples were injected into a UPLC system (Ultimate 3000, Thermo Scientific) and were analysed on positive mode: samples were loaded onto a Reprosil C18 column (2.0 mm × 150 mm, 2.5 μm - Dr Maisch, Germany) for metabolite separation. Chromatographic separations were achieved at a column temperature of 30 °C and flow rate of 0.2 mL/min. A linear gradient (0–100%) of solvent A (ddH2O, 0.1% formic acid) to B (acetonitrile, 0.1% formic acid) was employed over 20 minutes, returning to 100% solvent A in 2 minutes and a 6-minute post-time solvent A hold. Acetonitrile, formic acid, and HPLC-grade water were purchased from Sigma Aldrich.

High Resolution Mass Spectrometry (HRMS)
The UPLC system was coupled online with a mass spectrometer, Q Exactive (Thermo Scientific), scanning in full MS mode (2 μ scans) at a resolution of 70,000 in the 67 to 1000 m/z range, target of 1 × 106 ions and a maximum ion injection time (IT) of 35 ms, 3.8 kV spray voltage, 40 sheath gas, and 25 auxiliary gas, operated in negative and then positive ion mode. Source ionization parameters were: spray voltage, 3.8 kV; capillary temperature, 300 °C; and S-Lens level, 45. Calibration was performed before each analysis against positive or negative ion mode calibration mixes (Piercenet, Thermo Fisher, Rockford, IL) to ensure sub-ppm error of the intact mass.

Metabolite quantification
Data were normalized by urinary specific gravity because creatinine excretion may be abnormally reduced in autistic children [31]. Replicates were exported as mzXML files and processed through MAVEN [32]. Mass spectrometry chromatograms were elaborated for peak alignment, matching and comparison of parent and fragment ions, and tentative metabolite identification (within a 10-ppm mass deviation range between observed and expected results against the imported Kyoto Encyclopaedia of Genes and Genomes (KEGG) database .</r:Content>
    </r:Abstract>
    <r:Coverage>
      <r:TopicalCoverage>
        <r:URN>urn:ddi:se.researchdata:2024-444.TopicalCoverage:2.0</r:URN>
        <r:Subject xml:lang="en" controlledVocabularyID="Health.SpecificDiseasesDisordersAndMedicalConditions" controlledVocabularyName="CESSDA Topic Classification">Specific diseases, disorders and medical conditions</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="Health.SpecificDiseasesDisordersAndMedicalConditions" controlledVocabularyName="CESSDA Topic Classification">Specifika sjukdomar, störningar och medicinska tillstånd</r:Subject>
        <r:Subject xml:lang="en" controlledVocabularyID="3" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Medical and Health Sciences</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="3" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Medicin och hälsovetenskap</r:Subject>
        <r:Subject xml:lang="en" controlledVocabularyID="30215" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Psychiatry</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="30215" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Psykiatri</r:Subject>
        <r:Subject xml:lang="en" controlledVocabularyID="30401" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="30401" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Medicinsk bioteknologi (inriktn. mot cellbiologi (inkl. stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)</r:Subject>
        <r:Subject xml:lang="en" controlledVocabularyID="30114" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Evolution and Developmental Genetics</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="30114" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Evolution och utvecklingsgenetik</r:Subject>
        <r:Keyword xml:lang="en" controlledVocabularyID="F84" controlledVocabularyName="ICD-10">Pervasive developmental disorders</r:Keyword>
        <r:Keyword xml:lang="sv" controlledVocabularyID="F84" controlledVocabularyName="ICD-10">Genomgripande utvecklingsstörningar</r:Keyword>
        <r:Keyword xml:lang="en" controlledVocabularyID="D000067877" controlledVocabularyName="MeSH">Autism Spectrum Disorder</r:Keyword>
        <r:Keyword xml:lang="sv" controlledVocabularyID="D000067877" controlledVocabularyName="MeSH">Autismspektrumstörning</r:Keyword>
      </r:TopicalCoverage>
      <r:SpatialCoverage>
        <r:URN>urn:ddi:se.researchdata:2024-444.SpatialCoverage:2.0</r:URN>
        <r:CountryCode>SE</r:CountryCode>
      </r:SpatialCoverage>
    </r:Coverage>
    <r:AnalysisUnit controlledVocabularyID="AnalysisUnit" controlledVocabularyAgencyName="DDI Alliance">Individual<r:ControlledVocabularyURN>http://rdf-vocabulary.ddialliance.org/cv/AnalysisUnit/2.1.3/2dd4472</r:ControlledVocabularyURN></r:AnalysisUnit>
    <r:AnalysisUnitsCovered>
      <r:String xml:lang="en">Individual</r:String>
      <r:String xml:lang="sv">Individ</r:String>
    </r:AnalysisUnitsCovered>
    <d:DataCollection>
      <r:URN>urn:ddi:se.researchdata:2024-444.DataCollection:2.0</r:URN>
      <d:CollectionEvent>
        <r:URN>urn:ddi:se.researchdata:2024-444.CollectionEvent:2.0</r:URN>
        <d:DataCollectionDate />
        <d:ModeOfCollection>
          <r:URN>urn:ddi:se.researchdata:2024-444.CollectionEvent-0-ModeOfCollectionType:2.0</r:URN>
          <d:TypeOfModeOfCollection>Measurements and tests</d:TypeOfModeOfCollection>
          <r:Description>
            <r:Content xml:lang="en">Measurements and tests</r:Content>
            <r:Content xml:lang="sv">Mätningar och tester</r:Content>
          </r:Description>
        </d:ModeOfCollection>
      </d:CollectionEvent>
    </d:DataCollection>
    <a:Archive>
      <r:URN>urn:ddi:se.researchdata:2024-444.Archive:2.0</r:URN>
      <a:ArchiveSpecific>
        <a:Item>
          <a:Access>
            <r:URN>urn:ddi:se.researchdata:2024-444.Archive-ArchiveSpecificType-AccessType:2.0</r:URN>
            <a:TypeOfAccess controlledVocabularyName="info:eu-repo-Access-Terms vocabulary">restrictedAccess</a:TypeOfAccess>
          </a:Access>
          <a:DataFileQuantity>3</a:DataFileQuantity>
        </a:Item>
      </a:ArchiveSpecific>
    </a:Archive>
  </s:StudyUnit>
</ddi:DDIInstance>